- Home
- NTIP vs ECOR Comparison
NTIP vs ECOR Comparison
Compare NTIP & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- ECOR
- Stock Information
- Founded
- NTIP 1990
- ECOR 2005
- Country
- NTIP United States
- ECOR United States
- Employees
- NTIP N/A
- ECOR N/A
- Industry
- NTIP Multi-Sector Companies
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NTIP Miscellaneous
- ECOR Health Care
- Exchange
- NTIP Nasdaq
- ECOR Nasdaq
- Market Cap
- NTIP 32.0M
- ECOR 37.1M
- IPO Year
- NTIP 1998
- ECOR 2018
- Fundamental
- Price
- NTIP $1.62
- ECOR $4.92
- Analyst Decision
- NTIP
- ECOR Strong Buy
- Analyst Count
- NTIP 0
- ECOR 2
- Target Price
- NTIP N/A
- ECOR $25.50
- AVG Volume (30 Days)
- NTIP 58.3K
- ECOR 99.3K
- Earning Date
- NTIP 10-23-2025
- ECOR 08-06-2025
- Dividend Yield
- NTIP 6.17%
- ECOR N/A
- EPS Growth
- NTIP N/A
- ECOR N/A
- EPS
- NTIP N/A
- ECOR N/A
- Revenue
- NTIP $150,000.00
- ECOR $27,700,000.00
- Revenue This Year
- NTIP N/A
- ECOR $24.48
- Revenue Next Year
- NTIP N/A
- ECOR $44.35
- P/E Ratio
- NTIP N/A
- ECOR N/A
- Revenue Growth
- NTIP N/A
- ECOR 30.16
- 52 Week Low
- NTIP $1.16
- ECOR $4.16
- 52 Week High
- NTIP $1.90
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- NTIP 57.28
- ECOR 40.59
- Support Level
- NTIP $1.56
- ECOR $4.74
- Resistance Level
- NTIP $1.65
- ECOR $5.32
- Average True Range (ATR)
- NTIP 0.08
- ECOR 0.31
- MACD
- NTIP 0.01
- ECOR 0.00
- Stochastic Oscillator
- NTIP 42.42
- ECOR 19.01
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.